URANIUM ROYALTY CORP (UROY)

NASDAQFinancialsUraniumSnapshot 2026-11-04

$2.81-10.22%

Close 2026-11-05 · 1-day change

Investment OutlookAs of Nov 4, 2026

What could strengthen or challenge URANIUM ROYALTY CORP’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Nov 3, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

Matching fiscal periods, usable estimates and at least one analyst are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2027-01-31
Revenue	No revenue guidance available	84.89M
EPS	No EPS guidance available	-0.015
Annual ending 2027-04-30
Revenue	No revenue guidance available	85.23M
EPS	No EPS guidance available	0.088
Annual ending 2028-04-30
Revenue	No revenue guidance available	41.41M
EPS	No EPS guidance available	-0.022

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
EPS stays positive	A primary condition in URANIUM ROYALTY CORP's published investment case. The stated target is >= $0.09.	Intact	EPS turns negative for the full fiscal year	Diluted EPS: $0.10 per share FY2027-Q1; GAAP. Published target: >= $0.09. Annual target cannot be compared with a quarterly or TTM observation. Sep 14, 20260.1 USD/share · source valueLast status assessment Nov 4, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Revenue holds near $85M	A primary condition in URANIUM ROYALTY CORP's published investment case. The stated target is ~$85.2M.	Under Pressure	Revenue falls below $70M in the next fiscal year	Revenue: $50.967M FY2027-Q1; GAAP. Published target: ~$85.2M. Annual target cannot be compared with a quarterly or TTM observation. Sep 14, 202650,967,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Price recovers to fair value	A supporting condition in URANIUM ROYALTY CORP's published investment case. The stated target is Price approaches $19.05.	Under Pressure	Consensus target is cut below $10.00	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Nov 3, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2028 · fiscal year ending 2028-04-30 · fmp

FY2028 EPS$-0.02

$-0.02 → $-0.02 · observed estimates

FY2028 revenue$0.04B

$0.04B → $0.04B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2028 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-11-02	$-0.02	$41,410,447	1 / 1
2026-11-03	$-0.02	$41,410,447	1 / 1
2026-11-04	$-0.02	$41,410,447	1 / 1

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-06-01	4	0	0
2026-07-01	5	0	0
2026-08-01	5	0	0
2026-09-01	5	0	0
2026-10-01	5	0	0
2026-11-01	5	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 5 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades1 maintains

Recent actions · Oct 6–Nov 4 · 1 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

H.C. WainwrightOct 20

$4.50New observation · no comparable prior

$0$2.48$4.95

0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior

How this is measured

Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

EPS stays positiveDiluted EPS: $0.10 per share
Revenue holds near $85MPublished status: Under Pressure
Price recovers to fair valuePublished status: Under Pressure

Next proof point

Dec 10, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.5%Typical daily move · historical

Downside history

-35.1%Maximum drawdown · trailing year

Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.